KPW
XERS icon

Kore Private Wealth’s Xeris Biopharma Holdings XERS Stock Holding History

Kore Private Wealth’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,120
Closed -$41K – 474
2021
Q2 		$41K Buy
+10,120
New +$38.6K ﹤0.01% 421

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Kore Private Wealth's XERS Position: Q3 2021 in Review

Kore Private Wealth sold out of Xeris Biopharma Holdings (XERS) in Q3 2021, closing a stake of 10,120 shares — an estimated $41K sold.

Kore Private Wealth first reported a position in XERS in Q2 2021 and held it in 1 quarter. The position peaked at $41K in Q2 2021. 70 funds tracked by Wall St. Rank hold XERS as of Q3 2021.

  • Kore Private Wealth reported no remaining Xeris Biopharma Holdings position as of Q3 2021 after selling out during the quarter.
  • Kore Private Wealth sold 10,120 Xeris Biopharma Holdings shares in Q3 2021, an estimated $41K.
  • Kore Private Wealth first reported a position in Xeris Biopharma Holdings in Q2 2021 and held it in 1 quarter.
  • Kore Private Wealth's Xeris Biopharma Holdings position peaked at $41K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2021.

Based on Kore Private Wealth's 13F filing for Q3 2021, filed 15 Nov 2021.